Home › Breast Cancer › Kentucky
Breast Cancer clinical trials in Kentucky
23 studies for Breast Cancer are looking for participants at sites in Kentucky.
Cities in Kentucky
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Norton Cancer Institute, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Saint Joseph Hospital East, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Elizabeth Medical Center Edgewood, Edgewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
- University of Kentucky - Markey Cancer Center, Lexington
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- King's Daughter's Medical Center, Ashland
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
- and 1 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Kentucky Chandler Medical Center, Lexington
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Elizabeth Healthcare Edgewood, Edgewood
- and 5 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Flaget Memorial Hospital, Bardstown
- Saint Joseph Hospital East, Lexington
- Saint Joseph London, London
- and 2 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- King's Daughter's Medical Center, Ashland
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Baptist Health Corbin, Corbin
- and 15 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Baptist Health Lexington ( Site 0050), Lexington
- Baptist Health Hamburg ( Site 0071), Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07060807ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- University Medical Center, Inc. DBA University of Louisville Hospital/James Graham Brown Cancer Center, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07173751A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- St. Elizabeth Healthcare, Edgewood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- St. Elizabeth Edgewood Hospital, Edgewood
- Norton Cancer Institute - Downtown, Louisville
- Baptist Health Louisville, Louisville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Edgewood
- Research Site, Louisville
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 19, 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- University Medical Center, Inc. ; DBA UofL Health - UofL Hospital/Brown Cancer Center, Louisville
- UofL Health Brown Cancer Center Medical Center Northeast, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053), Edgewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06312176Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Mercy Health-Paducah Cancer Center, Paducah
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
RecruitingObservational studyHealthy volunteers welcome
Ages 45 and older · All sexes · Updated Jul 1, 2026 · NCT07186296Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- UK Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Saint Joseph Hospital, Lexington
- Saint Joseph Radiation Oncology Resource Center, Lexington
- Saint Joseph Hospital East, Lexington
- and 1 more
RecruitingPhase 3
Ages 50 to 70 · All sexes · Updated Apr 23, 2026 · NCT04852887A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
- James Graham Brown Cancer Center, Louisville
RecruitingPhase 2
Ages 18 and older · Women · Updated Feb 20, 2025 · NCT04990921From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.